• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    55.49 +0.95 (+1.74%)
    Streaming Delayed Price Updated: 2:13 PM EDT, Jul 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    36 37 Next >
    News headline image
    Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗
    The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
    Via Investor's Business Daily
    News headline image
    Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It ↗
    Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases. 
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    The Best Stocks to Invest $1,000 in Right Now ↗
    Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to bear more fruit. 
    Via The Motley Fool
    Topics Government World Trade
    News headline image
    The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip ↗
    Via The Motley Fool
    Topics Economy
    News headline image
    5 Monster Stocks to Hold for the Next 10 Years ↗
    These companies are just starting to realize the potential in up-and-coming fields, like AI and gene editing. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? ↗
    Via The Motley Fool
    News headline image
    Prediction: This Beaten-Down Stock Could Double in The Next 5 Years ↗
    Via The Motley Fool
    News headline image
    CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
    CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders 
    Via MarketBeat
    News headline image
    Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? ↗
    Via The Motley Fool
    News headline image
    2 Biotech Stocks That Are Screaming Buys in May ↗
    Via The Motley Fool
    News headline image
    Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? ↗
    The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. 
    Via The Motley Fool
    News headline image
    3 Monster Stocks to Hold for the Next 10 Years ↗
    The planets are lining up for these three stocks' underlying companies. 
    Via The Motley Fool
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs. 
    Via The Motley Fool
    Topics Artificial Intelligence World Trade
    News headline image
    CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst ↗
    CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025. 
    Via Benzinga
    News headline image
    Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗
    FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
    Via Benzinga
    News headline image
    These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results ↗
     
    Via Benzinga
    News headline image
    Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
     
    Via Benzinga
    News headline image
    Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks ↗
    The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program. 
    Via Investor's Business Daily
    Topics Government Intellectual Property
    News headline image
    Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant ↗
    On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs. 
    Via Benzinga
    News headline image
    2 Beaten-Down Stocks With Incredible Upside Potential ↗
    Via The Motley Fool
    News headline image
    5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years ↗
    Via The Motley Fool
    Topics Artificial Intelligence Economy
    News headline image
    3 Magnificent Stocks That Could Double or More by 2030 ↗
    Via The Motley Fool
    News headline image
    Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗
    Via The Motley Fool
    News headline image
    4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗
    Via The Motley Fool
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    The iconic growth investor made some interesting moves during Friday's market pullback. 
    Via The Motley Fool
    News headline image
    Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗
     
    Via Benzinga
    News headline image
    Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗
    Via The Motley Fool
    Topics Bankruptcy Economy World Trade
    News headline image
    Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗
    Via The Motley Fool
    Topics Government World Trade
    News headline image
    Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗
    Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
    Via Investor's Business Daily
    News headline image
    The Future of Healthcare: 10 Predictions For The Next Decade
    The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
    Via MarketMinute
    Topics Artificial Intelligence
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    36 37 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.